Arcam receives order from DiSanto Technology for two Arcam Q10 systems

NewsGuard 100/100 Score
Jun 24 2014

Arcam (STO:ARCM), listed on NASDAQ OMX, has received an order for two Arcam Q10 systems from the strategic partner DiSanto Technology Inc. in the US. The systems will be used for manufacturing of orthopedic implants.

In spring 2013 Arcam and Disanto Technology Inc. entered into a strategic cooperation in order to make a joint development of customers for contract manufacturing of advanced orthopedics implants based on Arcam´s EBM technology. In connection with the cooperation DiSanto bought two EBM systems. With this new order DiSanto increases its EBM based production.

"The cooperation with DiSanto is developing very well and with this new order DiSanto increases its manufacturing capacity to meet the demand on EBM manufactured implants", says Magnus René, CEO of Arcam.

Source:

Arcam AB

Posted in: Business / Finance | Device / Technology News

Tags: , , , ,

Comments (0)

Suggested Reading

New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses
Revolutionizing diabetes management with reliable blood glucose monitoring without finger pricking
Personality dictates binge-watching: Study reveals why we can't stop streaming
From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip
AI-based conversational agents show promise in young people's mental health interventions

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Novel SARS-CoV-2 mutations found in floodwaters near homeless communities